- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07324278
Hybrid Stroke Rehab With Mirror Priming
August 21, 2026 updated by: Yi-chun Li, I-Shou University
Hybrid Stroke Rehabilitation With Mirror Priming
This trial aims to examine the effects of enhanced mirror priming, overcoming the limitations of traditional mirror therapy, to achieve optimization and personalized intervention.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
81
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yi-chun Li, PhD
- Phone Number: 7514 +886-7-6151100
- Email: joyjoyfish@gmail.com
Study Locations
-
-
Yanchao District
-
Kaohsiung City, Yanchao District, Taiwan, 82445
- Recruiting
- E-Da Hospital
-
Contact:
- Yi-chun Li, PhD
- Phone Number: 7514 +886-7-6151100
- Email: joyjoyfish@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- A first-ever unilateral stroke ≥3 months
- Age between 20 and 80 years
- Baseline Fugl-Meyer Assessment Upper Extremity (FMA-UE) score ≥ 10
- No severe spasticity in any joints of the affected arm
- Ability to follow the instructions
- No participation in other studies during the study period
- Willingness to provide informed written consent.
Exclusion Criteria:
- Serious medical problems or poor physical conditions that might be detrimental to study participation.
- Received or planned botulinum toxin injections within 3 months prior to or during the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: High-dose enhanced mirror priming group
|
During the mirror priming process, the movement images of the participant's unaffected limb are mirrored to the affected side to provide visual feedback.
Conventional therapy is individualized and may include impairment-oriented, shaping, or whole-task practice.
|
|
Experimental: Low-dose enhanced mirror priming group
|
During the mirror priming process, the movement images of the participant's unaffected limb are mirrored to the affected side to provide visual feedback.
Conventional therapy is individualized and may include impairment-oriented, shaping, or whole-task practice.
|
|
Active Comparator: Active control group
|
Conventional therapy is individualized and may include impairment-oriented, shaping, or whole-task practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Fugl-Meyer Assessment
Time Frame: Baseline, 2 weeks, 4 weeks, and 3 months post-intervention.
|
Baseline, 2 weeks, 4 weeks, and 3 months post-intervention.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Grip and pinch power
Time Frame: Baseline, 4 weeks, and 3 months post-intervention.
|
Baseline, 4 weeks, and 3 months post-intervention.
|
|
Revised Nottingham Sensory Assessment
Time Frame: Baseline, 4 weeks, and 3 months post-intervention.
|
Baseline, 4 weeks, and 3 months post-intervention.
|
|
Berg Balance Scale
Time Frame: Baseline, 4 weeks, and 3 months post-intervention.
|
Baseline, 4 weeks, and 3 months post-intervention.
|
|
Motor Activity Log
Time Frame: Baseline, 4 weeks, and 3 months post-intervention.
|
Baseline, 4 weeks, and 3 months post-intervention.
|
|
ABILHAND Questionnaire
Time Frame: Baseline, 4 weeks, and 3 months post-intervention.
|
Baseline, 4 weeks, and 3 months post-intervention.
|
|
Chedoke Arm and Hand Activity Inventory
Time Frame: Baseline, 4 weeks, and 3 months post-intervention.
|
Baseline, 4 weeks, and 3 months post-intervention.
|
|
Stroke Impact Scale
Time Frame: Baseline, 4 weeks, and 3 months post-intervention.
|
Baseline, 4 weeks, and 3 months post-intervention.
|
|
Stroke Self-Efficacy Questionnaire
Time Frame: Baseline, 4 weeks, and 3 months post-intervention.
|
Baseline, 4 weeks, and 3 months post-intervention.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 2, 2026
Primary Completion (Estimated)
September 30, 2030
Study Completion (Estimated)
December 31, 2030
Study Registration Dates
First Submitted
December 23, 2025
First Submitted That Met QC Criteria
December 23, 2025
First Posted (Actual)
January 7, 2026
Study Record Updates
Last Update Posted (Actual)
August 25, 2026
Last Update Submitted That Met QC Criteria
August 21, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISU-OT-Li-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.